Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | PRKCG | P05129 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902536 | 0.85 | OPRK1 (0.36) | KCNA3L3MBTL3L3MBTL1KDM4EOPRK1 | |
| SCHEMBL2907788 | 0.85 | LMNA (0.37) | KCNA3MAPK1L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL2909897 | 0.78 | KCNH2 (0.56) | MAPK1KDM4EOPRK1OPRM1OPRD1 | |
| SCHEMBL2267354 | 0.77 | L3MBTL3 (0.53) | KCNA3L3MBTL3L3MBTL1KDM4EOPRK1 | |
| SCHEMBL2267306 | 0.77 | L3MBTL3 (0.53) | KCNA3L3MBTL3L3MBTL1KDM4EOPRK1 | |
| SCHEMBL2908249 | 0.75 | ALDH1A1 (0.44) | MAPK1L3MBTL1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL2908848 | 0.74 | LRRK2 (0.36) | GSK3B | |
| SCHEMBL2901677 | 0.74 | MAPT (0.39) | KDM4EALDH1A1MEN1KMT2AP4HB | |
| SCHEMBL2908342 | 0.72 | ITGB2 (0.38) | MAPK1L3MBTL1KDM4EALDH1A1MEN1 | |
| SCHEMBL5745466 | 0.69 | SLC6A9 (0.47) | KCNA3L3MBTL3L3MBTL1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | claimed |
| US-7566709-B2 | 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | claimed |
| US-7566709-B2 | 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | HTR1A, HTR1D, HTR5A | KCNA3 306/4885CDC7 4837/4885PLK4 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.